Carol Emerson
Psychiatric/Mental Health · Danvers, MANPI 1922412477
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,887 of the $6,872 with a category attached, or 85.7%. 19 manufacturers reported payments, led by Corium, LLC at 24.6% of the total. Reporting peaked in 2023 at $2,226 and has fallen 52.3% since, to $1,061 in 2025. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$2K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$763
- Takeda Pharmaceuticals U.S.A., Inc.$569
- Supernus Pharmaceuticals, Inc.$500
- Otsuka America Pharmaceutical, Inc.$410
- plus $2K from 13 others
What the payments were for
- Consulting fees$1733%
- Speaking & faculty fees$80512%
- Food & beverage$5,88786%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 46 | $1,688 |
| AbbVie | 70 | $1,187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $569 |
| Supernus Pharmaceuticals, Inc. | 31 | $500 |
| Otsuka America Pharmaceutical, Inc. | 23 | $410 |
| Idorsia Pharmaceuticals US Inc | 7 | $289 |
| Sunovion Pharmaceuticals Inc. | 34 | $251 |
| Alkermes, Inc. | 19 | $241 |
| Axsome Therapeutics, Inc. | 10 | $220 |
| Collegium Pharmaceutical, Inc. | 10 | $162 |
| Lundbeck LLC | 8 | $157 |
| Ironshore Pharmaceuticals Inc. | 3 | $134 |
| Johnson & Johnson | 1 | $90 |
| Neurocrine Biosciences, Inc. | 4 | $68 |
| Vertical Pharmaceuticals, LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Tempus AI, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,872 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 16 | $1,526 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $699 |
| Bupropion XlBupropion Hcl | 14 | $263 |
| Trazodone Hcl | 16 | $207 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $192 |
| Clonazepam | 22 | $144 |
| Lorazepam | 17 | $114 |
| Alprazolam | 18 | $85 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $77 |
| Zolpidem Tartrate | 28 | $44 |
| Quetiapine Fumarate | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Danvers
- Annamaria GraffeoDanvers$8K
- Kristen Skobe-RibeiroDanvers$6K
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.